Gilead Sciences | GILD - Gross Profit On Sales


Gilead Sciences reported $6.8B in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
AbbVie USD 14.39B 1.85B Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
ALKERMES USD 375.31M 43.98M Jun/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Amgen USD 5.87B 1.02B Mar/2026
Biogen USD 2.12B 307M Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 16.22B 301.7M Mar/2026
Gilead Sciences USD 6.8B 1.29B Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Pfizer USD -248M 11.29B Jun/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.71B 602M Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
United Therapeutics USD 683.8M 35.7M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026